EA200000685A1 - Комплекс ifnar2/ifn - Google Patents

Комплекс ifnar2/ifn

Info

Publication number
EA200000685A1
EA200000685A1 EA200000685A EA200000685A EA200000685A1 EA 200000685 A1 EA200000685 A1 EA 200000685A1 EA 200000685 A EA200000685 A EA 200000685A EA 200000685 A EA200000685 A EA 200000685A EA 200000685 A1 EA200000685 A1 EA 200000685A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ifn
complex
interferon
ifnar
covalent
Prior art date
Application number
EA200000685A
Other languages
English (en)
Other versions
EA003635B1 (ru
Inventor
Марк Теппер
Марк Каннингхэм
Дэвид Шеррис
Нэйбил Эл Тэйер
Син Маккенна
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н.В. filed Critical Апплайд Резеч Системз Арс Холдинг Н.В.
Publication of EA200000685A1 publication Critical patent/EA200000685A1/ru
Publication of EA003635B1 publication Critical patent/EA003635B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

(57) Эффект интерферона (IFN) типа I in vivo может быть пролонгирован путем введения интерферона в виде комплекса с интерферон-связывающей цепью рецептора человеческого интерферона α/β (IFNAR). Такой комплекс также улучшает стабильность IFN и повышает потенцию IFN. Этот комплекс может быть нековалентным комплексом, или комплексом, в котором IFN и IFNAR связаны ковалентной или пептидной связью. В случае связывания пептидной связью в форме слитого белка, IFN может быть отделен от IFNAR посредством пептидного линкера. Такой гибридный белок может быть получен с помощью технологии рекомбинантной ДНК. Хранение IFN в виде такого комплекса улучшает состояние при хранении IFN и позволяет хранить его при более мягких условиях, чем это возможно в других случаях.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000685A 1997-12-19 1998-12-18 Комплекс ifnar2/ifn EA003635B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6829597P 1997-12-19 1997-12-19
PCT/US1998/026926 WO1999032141A1 (en) 1997-12-19 1998-12-18 Ifnar2/ifn complex

Publications (2)

Publication Number Publication Date
EA200000685A1 true EA200000685A1 (ru) 2000-12-25
EA003635B1 EA003635B1 (ru) 2003-08-28

Family

ID=22081665

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000685A EA003635B1 (ru) 1997-12-19 1998-12-18 Комплекс ifnar2/ifn

Country Status (28)

Country Link
US (1) US6372207B1 (ru)
EP (1) EP1037658B1 (ru)
JP (1) JP4601163B2 (ru)
KR (1) KR100593981B1 (ru)
CN (1) CN1241638C (ru)
AR (1) AR020315A1 (ru)
AT (1) ATE218362T1 (ru)
AU (1) AU755078B2 (ru)
BG (1) BG64920B1 (ru)
BR (1) BR9813753A (ru)
CA (1) CA2311648C (ru)
DE (1) DE69805844T2 (ru)
DK (1) DK1037658T3 (ru)
EA (1) EA003635B1 (ru)
EE (1) EE200000355A (ru)
ES (1) ES2174530T3 (ru)
HK (1) HK1032914A1 (ru)
HU (1) HUP0100456A3 (ru)
IL (2) IL136855A0 (ru)
NO (1) NO20002691L (ru)
NZ (1) NZ504771A (ru)
PL (1) PL197568B1 (ru)
PT (1) PT1037658E (ru)
SK (1) SK9222000A3 (ru)
TR (1) TR200001961T2 (ru)
UA (1) UA74132C2 (ru)
WO (1) WO1999032141A1 (ru)
ZA (1) ZA9811634B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US7138379B2 (en) 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
IL147414A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7691975B2 (en) * 2003-08-25 2010-04-06 Toray Industries, Inc. Interferon-β complex
CN100400664C (zh) * 2005-09-06 2008-07-09 中国人民解放军第四军医大学 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法
EP2572734B1 (en) 2006-10-31 2016-04-06 East Carolina University Cytokine-based fusion proteins for treatment of immune disorders
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP3348275A3 (en) 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
EP2970461A4 (en) * 2013-03-15 2016-11-23 Janssen Biotech Inc INTERFERON ALPHA AND OMEGA ANTIBODY ANTAGONISTS
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
CN111050803A (zh) * 2017-06-20 2020-04-21 德克萨斯大学系统董事会 用于治疗癌症的干扰素前药
EP3672986A1 (en) 2017-08-22 2020-07-01 Sanabio, LLC Soluble interferon receptors and uses thereof
CN112646783B (zh) * 2020-12-30 2023-12-01 广州医科大学附属市八医院 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL106591A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
KR100593981B1 (ko) 2006-06-30
ES2174530T3 (es) 2002-11-01
DE69805844D1 (de) 2002-07-11
NO20002691D0 (no) 2000-05-25
HUP0100456A1 (hu) 2001-06-28
BG64920B1 (bg) 2006-09-29
UA74132C2 (ru) 2005-11-15
CN1241638C (zh) 2006-02-15
JP2001526242A (ja) 2001-12-18
NZ504771A (en) 2002-09-27
EE200000355A (et) 2001-10-15
EP1037658B1 (en) 2002-06-05
JP4601163B2 (ja) 2010-12-22
DK1037658T3 (da) 2002-09-30
HUP0100456A3 (en) 2003-09-29
HK1032914A1 (en) 2001-08-10
PT1037658E (pt) 2002-10-31
NO20002691L (no) 2000-08-18
PL197568B1 (pl) 2008-04-30
SK9222000A3 (en) 2001-01-18
KR20010032836A (ko) 2001-04-25
IL136855A (en) 2007-07-24
PL341423A1 (en) 2001-04-09
WO1999032141A1 (en) 1999-07-01
ZA9811634B (en) 1999-06-22
CN1282255A (zh) 2001-01-31
BR9813753A (pt) 2000-10-10
DE69805844T2 (de) 2002-10-24
AU755078B2 (en) 2002-12-05
EP1037658A1 (en) 2000-09-27
TR200001961T2 (tr) 2000-11-21
US6372207B1 (en) 2002-04-16
AR020315A1 (es) 2002-05-08
AU1926999A (en) 1999-07-12
ATE218362T1 (de) 2002-06-15
IL136855A0 (en) 2001-06-14
CA2311648A1 (en) 1999-07-01
CA2311648C (en) 2010-11-16
EA003635B1 (ru) 2003-08-28
BG104539A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
EA200000685A1 (ru) Комплекс ifnar2/ifn
DE69129803D1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
ES2107051T3 (es) Formulaciones de proteinas de liberacion sostenida.
EP0888122A4 (en) HYBRID FROM INTERFERON-alpha AND IMMUNGLOBULIN Fc FRAGMENT CONNECTED BY A MIGHTLY IMMUNOGENIC PEPTIDE
DE69934967D1 (de) Verfahren zur verminderung der immunogenität von proteinen
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
IL152886A0 (en) B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same
EA200100447A1 (ru) Гибридные белки на основе бета-интерферона и их применение
ATE318309T1 (de) Hcv-spezifische peptide, mittel dazu und ihre verwendung
JP2001506609A (ja) 生理活性の増加した多量体エリスロポエチン
ATE168719T1 (de) Osteogene peptide
ES2194838T3 (es) Enlazadores peptidicos ricos en serina.
DE69840150D1 (de) Verfahren, basierend auf affinitätskreuzbindung, der interaktion von biologisch aktiven peptiden an antikörper
KR950704489A (ko) 인터페론 타우 조성물 및 사용방법(interferon tau compositions and methods of use)
ATE278708T1 (de) Conotoxin peptid pviia
DE68927379D1 (de) Plättchen blockierende peptide
WO2002044197A3 (en) Cytokine receptor binding peptides
KR920012440A (ko) 인간 인터류킨-5 수용체
LV11816A (lv) Implantejama zalu forma
EA200000270A1 (ru) КОМПОЗИЦИИ ДЛЯ ГЕНОТЕРАПИИ С ИСПОЛЬЗОВАНИЕМ ГЕНОВ, КОДИРУЮЩИХ СЕКРЕТИРУЕМЫЕ БЕЛКИ, ТАКИЕ КАК β-ИНТЕРФЕРОН, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR0309921A (pt) Toxina relacionada a polipetìdeos, peptìdeo-mimético, anticorpo e ácido nucléico com atividade antimicrobiana e antiviral, bem como seu processo de preparação, sua composição farmacêutica e fabricação do medicamento
DE69635161D1 (de) Rekombinante hetero-multimerische proteine von dem alpha-beta c4 bp typ
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
KR920012114A (ko) 사람 면역결핍 바이러스(HIV)의 그룹-특이 항원(gaa)의 선택된 펩타이드, 이의 제법 및 용도

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU